• Gembine<sup>®</sup>
  • Gembine<sup>®</sup>

Gembine®

Gemcitabine Hydrochloride

Description
Gemcitabine Hydrochloride is a nucleoside analogue that exhibits antitumor activity. Gemcitabine Hydrochloride is 2'-deoxy-2',2'-difluorocytidine monohydrochloride (ß-isomer). The empirical formula for Gemcitabine Hydrochloride is C9H11F2N3O4 HCl. It has a molecular weight of 299.66. Gemcitabine Hydrochloride is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.

Indication
Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer. Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumors with or without metastases) in combination with cisplatin therapy. Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated. Ovarian Cancer: Gemcitabine in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who
have relapsed following platinum-based therapy.

 

Related Products